CN Patent

CN114213404B — Vegfr抑制剂替沃扎尼的合成工艺

Assigned to Wuhan Jiuzhou Yumin Medical Technology Co ltd · Expires 2024-08-06 · 2y expired

What this patent protects

本发明涉及一种VEGFR抑制剂替沃扎尼的合成工艺。本发明采用市售易得的原料，经过卤代反应、酯化反应、加成反应合成目标产物。总体来说，本发明所述的合成路线和合成工艺，简化了合成步骤，并且每步反应产率高、反应后处理简单，纯化大多采用打浆纯化，避免使用柱层析，操作过程简单，廉价，有利于应用至工业大生产中。

USPTO Abstract

本发明涉及一种VEGFR抑制剂替沃扎尼的合成工艺。本发明采用市售易得的原料，经过卤代反应、酯化反应、加成反应合成目标产物。总体来说，本发明所述的合成路线和合成工艺，简化了合成步骤，并且每步反应产率高、反应后处理简单，纯化大多采用打浆纯化，避免使用柱层析，操作过程简单，廉价，有利于应用至工业大生产中。

Drugs covered by this patent

tivozanib-hydrochloride (TIVOZANIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN114213404B
Jurisdiction: CN
Classification: —
Expires: 2024-08-06
Drug substance claim: No
Drug product claim: No
Assignee: Wuhan Jiuzhou Yumin Medical Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.